We are reporting results of the first clinical study in elderly volunteers with SRT2104, a compound belonging to a series of novel SIRT1 activators being developed for the treatment of type II diabetes and other-age related diseases [14], [15]. The gene discussed is SIRT1; the disease is type 2 diabetes mellitus.